-葡萄糖共运输体2抑制剂对心肌病的作用:一个元分析
Bo Xu1,2,3,4,5, Tianqiao Zhang1,2,3,4,5, Jiecan Zhou6,7,8,9,10
1The First Affiliated Hospital, Hunan Provincial Clinical Medical Research Center for Drug Evaluation of Major Chronic Diseases, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Journal of endocrinological investigation
|June 10, 2025
概括
-葡萄糖共运输体2 (SGLT2) 抑制剂显著降低心肌病风险. 这些发现强调了它们对心血管的益处,特别是对于心力衰竭和慢性病患者.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心肌病影响所有年龄段,并具有终身影响.
- -葡萄糖共运输体2 (SGLT2) 抑制剂对心肌病的影响需要进一步澄清.
研究的目的:
- 与安慰剂相比,评估SGLT2抑制剂在降低心肌病风险方面的有效性.
主要方法:
- 来自主要数据库的随机,双盲,安慰剂对照试验的系统审查.
- 使用Mantle-Haenszel方法的元分析,使用固定的效果模型和风险比率 (RR) 以95%的置信区间 (CI).
主要成果:
- 具有很高的确定性,SGLT2抑制剂可将心肌病风险降低28% (RR 0.72;95% CI 0.56-0.92).
- 在empagliflozin亚组,慢性病和心力衰竭人群中观察到显著的风险降低.
- 在2型糖尿病患者群体中,效果不那么明显;注意到初级和二级心肌病的风险降低.
结论:
- SGLT2 抑制剂对心肌病有显著的保护作用.
- 这些发现加强了SGLT2抑制剂在临床实践中的心血管优势,特别是在心力衰竭和CKD患者中.
相关概念视频
Heart Failure Drugs: Inotropic Agents
747
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
747
Cardiomyopathy V: Interprofessional Care
41
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
41
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
526
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
526
Cardiomyopathy II: Dilated Cardiomyopathy
30
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
30
Glucose Transporters
24.3K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
24.3K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.8K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.8K


